Generic Name and Formulations:
Rho (D) immune globulin human 1500 IU (300mcg)/2mL; syringe; for IV or IM inj; preservative- and latex-free; contains albumin (human); solvent/detergent treated.
Company:
CSL Behring, LLC
Raising platelet counts in Rho (D) positive non-splenectomized patients with chronic immune thrombocytopenic purpura (ITP).
See literature. 250 IU (50mcg) per kg by IV only at rate of 2mL per 15–60 seconds.
Not recommended.
Rho (D) positive patients. IgA deficiency.
Monitor patients 20 minutes after administration. Pregnancy (Cat.C).
Do not give live vaccines within 3 months.
Local or infusion reactions, fever, chills, headache; see literature.
Single-dose prefilled syringes—1, 10
Suppression of Rh isoimmunization in non-sensitized Rho (D) negative women during pregnancy and in appropriate obstetrical conditions, unless the fetus or father is known to be Rho (D) negative. Suppression of Rh isoimmunization in Rho (D) negative individuals transfused with Rho (D) positive blood products.
See literature. Pregnancy (28–30 weeks gestation), postpartum prevention (within 72 hours), obstetric complications, invasive procedures during pregnancy: 1500 IU (300mcg). Incompatible transfusions (within 72 hours): 100 IU (20mcg) per 2mL transfused blood or per 1mL erythrocyte concentrate.
Not recommended.
Rho (D) positive patients. IgA deficiency.
Monitor patients 20 minutes after administration. Pregnancy (Cat.C).
Do not give live vaccines within 3 months.
Local or infusion reactions, fever, chills, headache; see literature.
Single-dose prefilled syringes—1, 10